CLINICAL_TRIALS
trial_result
· 2013-02-21
Clinical Trial Update: STI571 in Treating Patients With Chronic Myelogenous Leukemia in Blast Crisis [Phase 2]
Summary
This update reports the completion of a Phase 2 trial evaluating imatinib (STI571) in patients with chronic myeloid leukemia in blast crisis.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Novartis | Conditions: Leukemia | Phase 2 | Status: COMPLETED